Bipolar Disorder Research
The Mood and Anxiety Disorders Program (MAP) is working to advance a range of new treatments for bipolar disorder. Our pharmaceutical studies include research to find new uses for existing medications such as minocycline (an FDA-approved antibiotic with promising antidepressant effects in bipolar cases) and to design new drugs. We are also studying more effective ways to use device-based therapies including Transcranial Magnetic Stimulation (TMS), in which a magnetic coil is placed against the forehead to stimulate nerves in the brain.
In addition to studying new treatments, MAP is using neuroimaging such as functional MRI (fMRI) to investigate brain activity during bipolar disorder in order to better understand the causes of this condition.
Clinical Trials for Bipolar Disorder
MAP is currently seeking individuals interested in participating in the following clinical trials for bipolar disorder.
- Minocycline for Bipolar Depression: Evaluates minocycline (an FDA-approved antibiotic) as a potential treatment for bipolar depression when added to a mood-stabilizing medication.
- Galantamine for Dysfunction in Bipolar Disorder: Examines the efficacy and safety of galantamine (an FDA-approved medication for treating Alzheimer's disease) compared to placebo in the treatment of bipolar patients with memory or attention difficulties.
- Deep Brain TMS for Bipolar Depression: Evaluates the efficacy and safety of H1-Coil deep brain rTMS (dTMS) in subjects with bipolar depression who are taking mood stabilizers and were previously unsuccessfully treated with antidepressant medications.
To participate in one of our clinical trials for Mood and Anxiety Disorders or to learn more about eligibility, please contact Katie Huryk (212-241-3089, email@example.com).